<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00608621</url>
  </required_header>
  <id_info>
    <org_study_id>ANA06103</org_study_id>
    <nct_id>NCT00608621</nct_id>
  </id_info>
  <brief_title>Influence of Physostigmine on Patient-Controlled Analgesia (PCA) in Postoperative Intensive Care Patients</brief_title>
  <acronym>ANA06103</acronym>
  <official_title>Influence of Physostigmine on Patient-Controlled Analgesia (PCA) in Postoperative Intensive Care Patients, Considering Pain Score, Opioid Consumption, Hemodynamics and Cognitive Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Klinikum Ludwigshafen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Mannheim</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Klinikum Ludwigshafen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is to evaluate the influence of physostigmine in the postoperative period in
      intensive care patients considering pain quality, opioid consumption, hemodynamics and
      mobilisation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pain management is of major concern in the postoperative period, mostly based on opioids. In
      numerous experimental and clinical trials cholinergic mechanisms have been demonstrated to
      play an important antinociceptive role. Physostigmine, a central cholineresterase inhibitor,
      has been shown to produce analgesia and enhance opiate analgesia after systemic injection.
      This action is not based on µ-receptor (opioid) activity, but can be mostly explained by
      stimulation of serotonine (5-HT-3) receptors. The major withdrawal of utilizating
      physostigmine in postoperative care, is due to its short duration of action.

      In the present study, we examined the effect of a continuous intavenous physostigmine
      application during a patient-controlled analgesia with piritramide for 48 hours compared to a
      placebo infusion with NaCl.

      Major concern was set for consumption of analgesics, VAS-pain scale, hemodynamics,
      mobilisation and side effects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>opioid consumption</measure>
    <time_frame>48 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>pain quality (VAS) mobilisation hemodynamics side effects</measure>
    <time_frame>operation to discharge from hospital</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">60</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>1-physostigmine</arm_group_label>
    <description>Physostigmine 4 mg in 50 ml NaCl 0.9% per 24 h as syringe pump continuously for 48 hours, plus physostigmine 2mg (in NaCl 0.9% 50 ml)at termination of sedation
PCA: Patient-controlled analgesia with piritramide 1 mg/ml, on demand: bolus of 2 mg, maximum of 10 mg in 60 min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2-placebo</arm_group_label>
    <description>NaCl 0.9% 50 ml per 24 h continuously over 48 hours, plus 50 ml NaCl 0.9% at termination of sedation
PCA: Patient-controlled analgesia with piritramid 1 mg/ml, on demand: bolus of 2 mg, maximum of 10 mg in 60 min</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Elective major surgery, postoperative ICU patients
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-80 years

          -  Indication for postoperative pain therapy and admission to ICU

          -  ASA I-III

          -  Weight 50-125 kg

          -  Patients that are willing to participate in the present study

        Exclusion Criteria:

          -  Peridural anesthesia for pain management

          -  Severe left ventricular function (EF &lt;30%)

          -  Severe/exacerbated COPD; Asthma

          -  ASA IV-V

          -  Chronic renal insufficiency(Creatinine &gt; 1,5 mg/dl)

          -  Ulcera ventriculi

          -  Known allergy to any of the study agents

          -  Hb preoperative &lt;9,5 g/dl

          -  Alcohol,drug and/or tablet abuse (Opioids, NSAR)

          -  Emergency operation

          -  Pregnancy

          -  Women of childbearing age and without a negative pregnancy test

          -  Severe liver disease (GOT oder GPT &gt; 45 U/L)

          -  Severe neurologica derangements (e.g. M. Parkinson, Multiple Sklerosis)

          -  History of apoplexia &lt;6 Monate or residua

          -  Perioperative myocardial infarction

          -  Patients that are not able to agree to the present study

          -  Patients that refuse to participate in the present study

          -  Patients that are part of any other study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christoph Konrad, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Mannheim, Department of Anesthesiology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kerstin D. Roehm, MD</last_name>
    <role>Study Director</role>
    <affiliation>Klinikum Ludwigshafen, Department of Anesthesiology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinkum Ludwigshafen, Department of Anesthesiology</name>
      <address>
        <city>Ludwigshafen</city>
        <zip>D-67063</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Beilin B, Bessler H, Papismedov L, Weinstock M, Shavit Y. Continuous physostigmine combined with morphine-based patient-controlled analgesia in the postoperative period. Acta Anaesthesiol Scand. 2005 Jan;49(1):78-84.</citation>
    <PMID>15675987</PMID>
  </reference>
  <reference>
    <citation>Röhm KD, Riechmann J, Boldt J, Schöllhorn T, Piper SN. Do patients profit from physostigmine in recovery from desflurane anaesthesia? Acta Anaesthesiol Scand. 2007 Mar;51(3):278-83. Epub 2007 Jan 23.</citation>
    <PMID>17250745</PMID>
  </reference>
  <reference>
    <citation>Aiello-Malmberg P, Bartolini A, Bartolini R, Galli A. Effects of morphine, physostigmine and raphe nuclei stimulation on 5-hydroxytryptamine release from the cerebral cortex of the cat. Br J Pharmacol. 1979 Apr;65(4):547-55.</citation>
    <PMID>435680</PMID>
  </reference>
  <reference>
    <citation>Passchier J, Rupreht J, Koenders ME, Olree M, Luitwieler RL, Bonke B. Patient-controlled analgesia (PCA) leads to more postoperative pain relief, but also to more fatigue and less vigour. Acta Anaesthesiol Scand. 1993 Oct;37(7):659-63.</citation>
    <PMID>8249554</PMID>
  </reference>
  <reference>
    <citation>Rupreht J, Schneck HJ, Dworacek B. [Physostigmine--recent pharmacologic data and their significance for practical use]. Anaesthesiol Reanim. 1989;14(4):235-41. Review. German.</citation>
    <PMID>2675888</PMID>
  </reference>
  <verification_date>December 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2008</study_first_submitted>
  <study_first_submitted_qc>February 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2008</study_first_posted>
  <last_update_submitted>February 5, 2008</last_update_submitted>
  <last_update_submitted_qc>February 5, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2008</last_update_posted>
  <responsible_party>
    <name_title>Klinikum Ludwigshafen, Dep. of Anesthesiology</name_title>
    <organization>Dr. K. D. Röhm</organization>
  </responsible_party>
  <keyword>physostigmine</keyword>
  <keyword>postoperative analgesia</keyword>
  <keyword>pain</keyword>
  <keyword>patient-controlled analgesia</keyword>
  <keyword>Opioid consumption</keyword>
  <keyword>Pain quality (VAS Score)</keyword>
  <keyword>Hemodynamics</keyword>
  <keyword>Mobilisation</keyword>
  <keyword>Side effects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Physostigmine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

